Cortexa Therapeutics is a biotech startup dedicated to developing transformative treatments for Amyotrophic Lateral Sclerosis (ALS). Founded by a Marine Corps officer diagnosed at 31, our mission is deeply personal and driven by an urgent need for innovation. Unlike conventional approaches, we target ALS at its root—focusing on the core mechanisms of neuronal degeneration. Our strategy centers on the simultaneous, precision modulation of two critical disease pathways—a dual-approach that remains untapped in current clinical trials.

ALS remains one of the most challenging neurodegenerative diseases, with limited treatment options. At Cortexa Therapeutics, we believe that by addressing excitotoxicty and calcium dysregulation, we can disrupt the underlying disease process and offer real hope to patients. With a streamlined approach to drug development, we are committed to pushing our first treatment into human trials within a year-because ALS patients don’t have time to wait.

While our immediate focus is ALS, our research into treating this specific pathology could have implications in other neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and frontotemporal dementia (FTD). By pioneering new strategies for neuroprotection and cellular resilience, we aim to lay the groundwork for treatments that extend beyond ALS.

We are not just another biotech company-we are a mission driven force committed to changing the future of ALS treatment. The time for new ideas is now, and at Cortexa Therapeutics, we are leading the way.